This version was published on 1 November 2008
Ann Clin Biochem 2008;
45:617-618
doi:10.1258/acb.2008.081101
© 2008 Association for Clinical Biochemistry
Letters
Revised national guidelines for analysis of CSF for bilirubin in suspected SAH
We are pleased to see the evolution of the UK guidelines in
this area (
Ann Clin Biochem 2008;
45:238–244), although
contest the view that analysis of bilirubin in CSF using diazo
methods has not been adequately validated in this context and
should not be used.
1 We developed such an approach to diagnosis,
2,3 now used routinely in our laboratory to identify approximately
90% of samples that do not need to be submitted to spectrophotometry.
Our approach employs the measurement of CSF bilirubin on an
automated instrument, using the Jendrassik and Gróf method,
calibrated to measure lower concentrations.
2 We found that at
a CSF bilirubin cut-off of 359 nmol/L, based on our upper reference
interval in CSF, there was 100% negative predictive value
2 for
a net bilirubin absorbance greater than 0.007, i.e. positive
initial scan. In a follow-up study,
3 the validity of this cut-off
was confirmed, with no evidence from clinical records to suggest
that any case of SAH had been missed. The accompanying editorial,
4 acknowledged that it could thus act as an initial screening
method to eliminate those samples that would subsequently prove
to be negative spectrophotometrically, thereby allowing the
majority of samples to be screened out by a procedure potentially
available on a 24-hour basis. An added advantage is that small
volumes of sample, around 100 µL (compared with 0.5 mL
needed for disposable cuvettes for absorbance scans) are sufficient
for the CSF bilirubin determination.
3 Preliminary data suggest
some negative interference of haemoglobin on CSF bilirubin,
which requires further study and quantitation, although it also
affects NBA derived by spectrophotometry. For operational purposes,
CSF samples are also submitted to spectrophotometry if our analyser
haemolytic index is greater than 2.0 mg/dL.
We believe that this methodology should be easily transferable to similar analytical platforms, although it is imperative that each laboratory should meticulously validate its own analytical performance. It offers a robust test and may be particularly useful in peripheral laboratories as a screen to identify those samples that need to be confirmed by spectrophotometry.3
C M Florkowski,
S J Southby and
P M George
Canterbury Health Laboratories, PO Box 151, Christchurch, New Zealand
 |
REFERENCES
|
|---|
- Cruickshank A, Auld P, Beetham R et al. Revised national guidelines for analysis of cerebrospinal fluid bilirubin for bilirubin in suspected subarachnoid haemorrhage. Ann Clin Biochem 2008;45:238–44[Abstract/Free Full Text]
- Chao C-Y, Florkowski CM, Fink JN, Southby SJ, George PM. Prospective validation of cerebrospinal fluid bilirubin in suspected subarachnoid haemorrhage. Ann Clin Biochem 2007;44:140–4[Abstract/Free Full Text]
- Ungerer JPJ, Southby SJ, Florkowski CM, George PM. Measurement of cerebrospinal fluid bilirubin in suspected subarachnoid hemorrhage. Clin Chem 2004;50:1854–6[Free Full Text]
- Beetham R. CSF bilirubin-spectrophotometry or direct measurement? Ann Clin Biochem 2007;44:99–100[Free Full Text]

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?